Cigna Reports $1.861 Billion Net Income in Q1 2026, Driven by Revenue Growth

The Cigna Group reported a net income of $1.861 billion for the first quarter of 2026, reflecting a 32% increase from $1.409 billion in the same period last year. This growth was primarily driven by a 25% rise in shareholders' net income, which reached $1.654 billion, up from $1.323 billion in 2025. Total revenues for the quarter amounted to $68.494 billion, a 5% increase compared to $65.502 billion in the prior year. The increase in revenue was largely attributed to an 11% rise in pharmacy revenues, which reached $54.037 billion, and a 14% increase in fees and other revenues, totaling $4.443 billion.

In contrast, premiums decreased by 23% to $9.812 billion, primarily due to the impact of the divestiture of the Medicare Advantage and related businesses to Health Care Services Corporation (HCSC) in March 2025. The filing indicated that the HCSC transaction negatively affected premium revenues by approximately 30%. Medical costs and other benefit expenses decreased by 25% to $7.924 billion, also influenced by the HCSC transaction, which accounted for a 32% reduction in medical costs. Selling, general, and administrative expenses decreased by 12% to $3.722 billion, further contributing to the improved profitability.

Cigna's operational metrics showed a slight increase in medical customers, which rose by 2% to 18.334 million, driven by growth in the Middle Market and Select segments. However, the U.S. Healthcare segment experienced a 6% decline in customers, totaling 2.493 million. The company also reported a significant increase in unpaid claims and claim expenses, which rose to $4.920 billion from $4.241 billion at the end of 2025, primarily due to seasonal factors related to stop-loss insurance.

Strategically, Cigna has been focusing on enhancing its operational efficiency through its Strategic Optimization Program, which has incurred costs of $380 million in the first quarter of 2026, compared to $215 million in the same period last year. The program aims to improve the overall experience for patients and providers while streamlining operations. Looking ahead, Cigna anticipates continued growth in its pharmacy and healthcare services, although it remains cautious about potential market fluctuations and regulatory changes that could impact its operations. The company maintains a strong liquidity position, with $7.3 billion in cash and short-term investments as of March 31, 2026, and no outstanding balance under its commercial paper program.